ESSA Pharma Inc.: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei ESSA Pharma Inc. listata cu simbolul CA.EPI ==Descriere companie== ESSA Pharma Inc. (www.essapharma.com) is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The Company is evaluating EPI...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei ESSA Pharma Inc. listata cu simbolul CA.EPI | Pagina dedicata companiei ESSA [[PHARMA|Pharma]] Inc. listata cu simbolul CA.EPI | ||
==Descriere companie== | ==Descriere companie== | ||
ESSA Pharma Inc. (www.essapharma.com) is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The Company is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments. | [[ESSA PHARMA|ESSA Pharma]] Inc. (www.essapharma.com) is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The Company is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||